Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ditylin-Biolik (Дитилін-Біолік) is an approved depolarizing neuromuscular blocking agent developed and manufactured by Biolik Biopharmaceutical in Ukraine. Its active ingredient is suxamethonium iodide (also known as succinylcholine iodide), a small molecule that acts as a short-acting muscle relaxant. Structurally resembling two joined molecules of acetylcholine, it binds to nicotinic receptors at the neuromuscular junction, causing persistent depolarization of the motor endplate and subsequent skeletal muscle paralysis. It is primarily indicated for facilitating tracheal intubation, providing muscle relaxation during endoscopic procedures (such as bronchoscopy or esophagoscopy), and maintaining myoplegia during short surgical interventions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ditylin-Biolik.